Published in:
01-12-2015 | Clinical Investigation
Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications
Authors:
Ulrik Carling, Eric J. Dorenberg, Sven-Petter Haugvik, Nils Andreas Eide, Dag Tallak Berntzen, Bjørn Edwin, Svein Dueland, Bård Røsok
Published in:
CardioVascular and Interventional Radiology
|
Issue 6/2015
Login to get access
Abstract
Purpose
The purpose of this study was to evaluate treatment response and complications of transarterial chemoembolization using drug-eluting beads loaded with irinotecan (DEBIRI) in patients with liver metastases from uveal melanoma (UM).
Materials and Methods
Patients treated with DEBIRI (n = 14) were retrospectively analyzed regarding overall survival, compared to patients (n = 14) treated with intravenous dacarbazine (DTIC). Median overall survival was calculated from time of diagnosis of metastatic disease (OS1) and start of treatment (OS2). Radiological response for DEBIRI was assessed according to RECIST 1.1 on contrast-enhanced computed tomography (CT), obtained 1.5 months (range 1.2–3.7) post treatment. Major complications of DEBIRI were defined according to the Society of Interventional Radiology classification for complications by outcome.
Results
In the DEBIRI group, OS1 was 14.8 months (range 3.9–47.5), and OS2 was 9.4 months (range 1.7–39). Further, 11/13 (84.6 %) of these patients had progressive disease on first follow-up CT and new lesions were seen in nine. There were 12 major complications in nine patients, possibly including one case of mortality due to disseminated intravascular coagulation (DIC).
Conclusion
For patients with liver metastases from UM, the effect on overall survival of DEBIRI alone is questionable. Compared to previous reports, the response rate of DEBIRI was poor, with new liver lesions observed in the majority of patients. Major complications possibly included one case of DIC.